TrialNature communications2023
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.
Dongliang Bian et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
37 papers cite it
this paperpooled ittrialcites it